Skip to content

Study · Not a test of the peptide alone · 2010

1 result

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.

Schildgen V, Ziegler S, Tillmann RL, Schildgen O

Virology journal21 Jul 2010Cited by 6 (Europe PMC)

PMID20646332 (opens in a new tab)PMCIDPMC2914674 (opens in a new tab)DOI10.1186/1743-422x-7-167 (opens in a new tab)PepBankPUB-20646332
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

ContextChronic HBV infection is a major cause of hepatocellular carcinoma (HCC) which meanwhile has become the 5th most reason for a fatal outcome of cancer. Worldwide, approximately 350 million people are chronically HBV infected and as such of risk to develop HCC, of those an estimated high rate of children. Treatment of chronic infection is sufficient to reduce the rate of HCC but the rate of sustained virological response remains to low, not at least due to emergence of resistant virus strains. Less is known on HBV infection in children despite the extremely high rate of chronicity.Objective, design, setting, and patientThe case of a nine years old male with a 6 year history of chronic HBV infection, of those 5 years with antiviral treatment is described.Interventions and main outcome measure(s)Before our lab was consulted, the patient was unsuccessfully treated with interferon, an obscure drug named Hepon, which should activate antiviral immune response, and Lamivudine, the latter most likely becoming ineffective due to the mergence of resistant subpopulations (rtL180 M, rtV207 M, two strains with stop codons at position rt188 and rt198, rtM204V (YVDD), rtM204K (YKDD)). Replacement of Lamivudine by adefovir displayed no advantage despite the lack of resistance mutations, thus no decrease in viremia was observed under adefovir treatment.Results and conclusionsNovel mutations in the YMDD motif and its direct neighbourhood were observed, both being compatible with Lamivudine resistance. No mutations were found that are associated with ADF resistance. Both, the clinical course of treatment and the genotypic resistance profile emphasize the need for systematic analyses of the HBV resistance mechanisms and structured therapy concept also for children chronically infected with HBV.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Gepon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gepon.

  1. 01HumanNot a test of Gepon aloneCase report or seriesEfficacy outcome

    In a child with chronic HBV infection, prior treatment with interferon, Hepon and lamivudine was unsuccessful.

    In plain wordsIn a child with chronic hepatitis B, prior treatment with interferon, Hepon and lamivudine was unsuccessful.

    Peptide
    Gepon
    Outcome
    Direction not reportedUnsuccessful treatment of chronic HBV infection
    Study

    n = 1

    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    Before our lab was consulted, the patient was unsuccessfully treated with interferon, an obscure drug named Hepon, which should activate antiviral immune response, and Lamivudine
    1 context sentence
    Summary · context
    The case of a nine years old male with a 6 year history of chronic HBV infection, of those 5 years with antiviral treatment is described.

    In this study, Gepon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gepon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.